More recently, AML molecular profile was found to correlate with outcome in patients treated with venetoclax combined to cytarabine or azacytidine, as patients harboring TP53, N/KRAS, SF3B1, or EZH2 mutations had a short survival probability [24]. This evidence concerns the gene SF3B1 and acute myeloid leukemia.